Yahoo
NYSE USD

Takeda Pharmaceutical Company Limited (TAK)

20.91 +0.90 (+4.50%)
At close: October 30 at 4:00:03 PM EDT
20.91 0.00 (0.00%)
After hours: October 30 at 5:26:18 PM EDT
Trade TAK on Coinbase
TAK Q2 2027 earnings call
Replay the call for the latest insights.
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
4,693,236,000
4,505,720,000
4,581,551,000
4,263,762,000
4,027,478,000
Cost of Revenue
1,605,621,000
1,571,588,000
1,580,217,000
1,426,678,000
1,244,072,000
Gross Profit
3,087,615,000
2,934,132,000
3,001,334,000
2,837,084,000
2,783,406,000
Operating Expense
2,417,592,000
2,469,681,000
2,534,964,000
2,527,183,000
2,195,594,000
Operating Income
670,023,000
464,451,000
466,370,000
309,901,000
587,812,000
Net Non Operating Interest Income Expense
-159,679,000
-143,774,000
-160,554,000
-140,463,000
-123,385,000
Other Income Expense
-512,815,000
-463,032,000
-130,730,000
-116,645,000
-89,336,000
Pretax Income
-2,471,000
-142,355,000
175,084,000
52,791,000
375,090,000
Tax Provision
-43,512,000
9,770,000
66,941,000
-91,406,000
58,052,000
Net Income Common Stockholders
40,795,000
-152,390,000
107,928,000
144,067,000
317,017,000
Diluted NI Available to Com Stockholders
40,795,000
-152,390,000
107,928,000
144,067,000
317,017,000
Basic EPS
12.11
-48.38
34.18
46.05
102.14
Diluted EPS
11.16
-48.38
33.62
45.58
100.97
Basic Average Shares
3,166,433
3,150,124
3,157,746
3,128,900
3,103,618
Diluted Average Shares
3,166,801
3,150,124
3,210,646
3,160,686
3,139,744
Total Operating Income as Reported
159,395,000
6,217,000
342,586,000
214,075,000
490,505,000
Total Expenses
4,023,213,000
4,041,269,000
4,115,181,000
3,953,861,000
3,439,666,000
Net Income from Continuing & Discontinued Operation
40,795,000
-152,390,000
107,928,000
144,067,000
317,017,000
Normalized Income
348,744,400
124,123,000
186,213,145.37
230,569,706.80
404,178,994.82
Interest Income
-62,099,000
16,878,000
19,638,000
11,293,000
5,508,000
Interest Expense
85,051,000
148,123,000
137,311,000
119,535,000
116,973,000
Net Interest Income
-159,679,000
--
-160,554,000
--
-123,385,000
EBIT
82,580,000
5,768,000
312,395,000
172,326,000
492,063,000
EBITDA
764,562,000
726,895,000
1,073,791,000
900,328,000
1,156,463,000
Reconciled Cost of Revenue
1,438,906,000
1,484,005,000
1,462,054,000
1,350,793,000
1,122,115,000
Reconciled Depreciation
681,982,000
721,127,000
761,396,000
728,002,000
664,400,000
Net Income from Continuing Operation Net Minority Interest
40,795,000
-152,390,000
107,928,000
144,067,000
317,017,000
Total Unusual Items Excluding Goodwill
-513,249,000
-460,855,000
-126,744,000
-123,118,000
-103,122,000
Total Unusual Items
-513,249,000
-460,855,000
-126,744,000
-123,118,000
-103,122,000
Normalized EBITDA
1,277,811,000
1,187,750,000
1,200,535,000
1,023,446,000
1,259,585,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-205,299,600
-184,342,000
-48,458,854.63
-36,615,293.20
-15,960,005.18
3/31/2023 - 1/5/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: